Single-nucleotide polymorphisms in the p53 pathway genes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent

Molecular Carcinogenesis

Volumn 49, Issue 6, 2010, Pages 545-555

  Yarden, Ronit I ^a,d   Friedman, Eitan ^b   Metsuyanim, Sally ^a   Olender, Tzvia ^c   Ben Asher, Edna ^c   Papa, Moshe Z ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

AKT1; BRCA1; BRCA2; Breast and ovarian cancer risk; CHEK2; Chk2; Jewish Ashkenazi population; Modifier genes; p53; PERP; ZBKR1 ZNF350

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DNA DAMAGE; DNA MODIFICATION; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JEWS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77953903603     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20618     Document Type: Article

References (43)

1. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [see comments]. N Engl J Med 1997;336:1401-1408. (Pubitemid 27208598)
2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
3. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006;2:257-274.
4. Narod SA, Foulkes WD. BRCA1 and BRC A2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676.
5. Phillips KA, Nichol K, Ozcelik H, et al. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 1999;91:469-473. (Pubitemid 29128285)
6. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: Functional aspects. Hum Mutat 2003;21:301-306.
7. Sullivan A, Yuille M, Repellin C, et al. Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 2002;21:1316-1324.
8. Yarden RI, Papa MZ. BRCA1 at the crossroad of multiple cellular pathways: Approaches for therapeutic interventions. Mol Cancer Ther 2006;5:1396-1404.
9. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-283.
10. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene 2002;21:8994-9007.
11. Xu X, Qiao W, Linke SP, et al. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis cell cycle and tumorigenesis. Nat Genet 2001;28:266-271. (Pubitemid 32626030)
12. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 2008;111:497-504.
13. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602.
14. Ogawara Y, Kishishita S, Obata T, et al. Akt enhancesMdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002;277:21843-21850. (Pubitemid 34952337)
15. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 2002;21:1299-1303. (Pubitemid 34185247)
16. Carpten JD, Faber AL, Horn C, et al. Atransforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-444.
17. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 2008;98:1533-1535.
18. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-429. (Pubitemid 38340288)
19. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300. (Pubitemid 30106484)
20. Ahn J, Prives C. Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J Biol Chem 2002;277:48418-48426. (Pubitemid 35470799)
21. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001;410:842-847. (Pubitemid 32303786)
22. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2000;404:201-204. (Pubitemid 30154490)
23. McPherson JP, Lemmers B, Hirao A, et al. Collaboration of Brca1 and Chk2 in tumorigenesis. Genes Dev 2004;18:1144-1153.
24. Kim SS, Cao L, Li C, et al. Uterus hyperplasia and increased carcinogen-induced tumorigenesis in mice carrying a targeted mutation of the Chk2 phosphorylation site in Brca1. Mol Cell Biol 2004;24:9498-9507.
25. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Lowpenetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-59.
26. Bell DW, Kim SH, Godwin AK, et al. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007;121:2661-2667.
27. Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Isr Med Assoc J 2007;9:791-796. (Pubitemid 350200978)
28. Harkin DPBJ, Miklos D, Song YH, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999;97:575-586.
29. Zheng LPH, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, Lee WH. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 2000;6:757-768.
30. Yun J, Lee WH.Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage. Mol Cell Biol 2003;23:7305-7314. (Pubitemid 37211010)
31. Rutter JL, Smith AM, Davila MR, et al. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat 2003;22:121-128.
32. Desjardins S, Belleau P, Labrie Y, et al. Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. Int J Cancer 2008;122:108-116.
33. Ihrie RA, Reczek E, Horner JS, et al. Perp is a mediator of p53-dependent apoptosis in diverse cell types. Curr Biol 2003;13:1985-1990.
34. Davies L, Gray D, Spiller D, et al. P53 apoptosis mediator PERP: Localization, function and caspase activation in uveal melanoma. J Cell Mol Med 2009;13:1995-2007.
35. Harris SL, Gil G, Robins H, et al. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc Natl Acad Sci USA 2005;102:16297-16302.
36. Atwal GS, Bond GL, Metsuyanim S, et al. Haplotype structure and selection of the MDM2 oncogene in humans. Proc Natl Acad Sci USA 2007;104:4524-4529.
37. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 2007;12:303-312.
38. Serrano-Fernandez P, Debniak T, Gorski B, et al. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Res Treat 2009;117:161-165.
39. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24:708-718.
40. Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 2007;27:1007-1016.
41. Kadouri L, Kote-Jarai Z, Hubert A, et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk inBRCA2carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer 2004;90:2002-2005. (Pubitemid 38746344)
42. Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies. Am J Hum Genet 2007;81:1186-1200.
43. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997;3:721-722.